206 related articles for article (PubMed ID: 31641524)
1. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors.
Fadini GP; Sarangdhar M; De Ponti F; Avogaro A; Raschi E
BMJ Open Diabetes Res Care; 2019; 7(1):e000725. PubMed ID: 31641524
[TBL] [Abstract][Full Text] [Related]
2. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
3. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Bonora BM; Raschi E; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier's gangrene.
Yang JY; Wang T; Pate V; Buse JB; Stürmer T
BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958306
[TBL] [Abstract][Full Text] [Related]
5. Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials.
Silverii GA; Dicembrini I; Monami M; Mannucci E
Diabetes Obes Metab; 2020 Feb; 22(2):272-275. PubMed ID: 31637829
[TBL] [Abstract][Full Text] [Related]
6. A Case of Fournier's Gangrene in a Patient Taking Canagliflozin for the Treatment of Type II Diabetes Mellitus.
Elbeddini A; Gallinger J; Davey M; Brassard S; Gazarin M; Plourde F; Aly A
Am J Case Rep; 2020 Feb; 21():e920115. PubMed ID: 32089542
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
Fadini GP; Bonora BM; Avogaro A
Diabetologia; 2017 Aug; 60(8):1385-1389. PubMed ID: 28500396
[TBL] [Abstract][Full Text] [Related]
8. Fournier's Gangrene under Sodium-Glucose Cotransporter-2 Inhibitors Therapy in Gynecological Patients.
Serrano Olave A; Bueno Moral AI; Martínez Bañón C; González Mesa E; Jiménez López JS
Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627798
[TBL] [Abstract][Full Text] [Related]
9. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Bersoff-Matcha SJ; Chamberlain C; Cao C; Kortepeter C; Chong WH
Ann Intern Med; 2019 Jun; 170(11):764-769. PubMed ID: 31060053
[TBL] [Abstract][Full Text] [Related]
10. Fournier's Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors.
Suciu IM; Greluș A; Cozlac AR; Suciu BS; Stoica S; Luca S; Luca CT; Gaiță DI
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38793020
[TBL] [Abstract][Full Text] [Related]
11. Fournier's gangrene in a patient on dapagliflozin treatment for type 2 diabetes.
Onder CE; Gursoy K; Kuskonmaz SM; Kocer U; Culha C
J Diabetes; 2019 May; 11(5):348-350. PubMed ID: 30604507
[No Abstract] [Full Text] [Related]
12. Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Elbeddini A; Tayefehchamani Y; Davey M; Gallinger J; Hooda N; Aly A; Erickson D; Lee S
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33526523
[TBL] [Abstract][Full Text] [Related]
13. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
15. A Rare but Life-Threatening Case of Fournier's Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin.
Jahir T; Hossain S; Bagum M; Saidi A; Risal R; Schmidt M
Cureus; 2022 Sep; 14(9):e29264. PubMed ID: 36262942
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
Bonora BM; Avogaro A; Fadini GP
Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
[TBL] [Abstract][Full Text] [Related]
17. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
18. Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs.
Katsuhara Y; Ikeda S
Clin Drug Investig; 2021 Mar; 41(3):235-243. PubMed ID: 33564981
[TBL] [Abstract][Full Text] [Related]
19. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
Lin DS; Lee JK; Chen WJ
J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
[TBL] [Abstract][Full Text] [Related]
20. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
